A Korean Multi-Center Survey about Warfarin Management before Gastroenterological Endoscopy in Patients with a History of Mechanical Valve Replacement Surgery.
10.5090/kjtcs.2016.49.5.329
- Author:
Kuk Hui SON
1
;
Chang Hyu CHOI
;
Jae Ik LEE
;
Kun Woo KIM
;
Ji Sung KIM
;
So Young LEE
;
Kook Yang PARK
;
Chul Hyun PARK
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Gachon University Gil Medical Center, Gachon University College of Medicine, Korea. cdgpch@gilhospital.com
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Heart valve prosthesis;
Anticoagulants;
Endoscopy;
Hemorrhage;
Thromboembolism
- MeSH:
Anticoagulants;
Aortic Valve;
Biopsy;
Endoscopy*;
Endoscopy, Digestive System;
Heart Valve Prosthesis;
Hemorrhage;
Heparin;
Humans;
International Normalized Ratio;
Korea;
Mitral Valve;
Risk Factors;
Surgeons;
Thromboembolism;
Warfarin*
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2016;49(5):329-336
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Guidelines for esophagogastroduodenoscopy (EGD) in the West allow the continued use of warfarin under therapeutic international normalized ratio (INR) level. In Korea, no guidelines have been issued regarding warfarin treatment before EGD. The authors surveyed Korean cardiac surgeons about how Korean cardiac surgeons handle warfarin therapy before EGD using a questionnaire. Participants were requested to make decisions regarding the continuation of warfarin therapy in two hypothetical cases. METHODS: The questionnaire was administered to cardiac surgeons and consisted of eight questions, including two case scenarios. RESULTS: Thirty-six cardiac surgeons at 28 hospitals participated in the survey, and 52.7% of the participants chose to stop warfarin before EGD in aortic valve replacement patients without risk factors for thromboembolism. When the patient’s INR level was 2, 31% of the participants indicated that they would choose to continue warfarin therapy. For EGD with biopsy, 72.2% of the participants chose warfarin withdrawal, and 25% of the participants chose heparin replacement. In mitral valve replacement patients, 47.2% of the participants chose to discontinue warfarin, and 22.2% of the participants chose heparin replacement. For EGD with biopsy in patients with a mitral valve replacement, 58.3% of the participants chose to stop warfarin, and 41.7% of the participants chose heparin replacement. CONCLUSION: This study demonstrated that attitudes regarding warfarin treatment for EGD are very different among Korean surgeons. Guidelines specific to the Korean population are required.
